Genmab — Juni 2018

[Sukkeralf]

or JNJ misinforming on purpose

[E_L]

unfortunately a lot of investors will not know the difference between solids, MM and all that ; they see a failure, they already had a 25% drop, and they flee. On top of that, they see in the newspaper that CART is going to cure cancer, so why would anyone need Dara? Markets are far from perfect...

[Sukkeralf]

But right now we lack buyers that understand that "everything is all right" - and there should be plenty of them as well

[Sukkeralf]

...and we dont see them at all - and this tells me that also many analyst had way to high hopes for Dara in solids even though they didnt have added any value in their models

[E_L]

yes, well, analysts..., no i don't understand that either…

[gentogen]

Med hensyn til dagens tidligere diskussion, så er problemet vel, at Medwatch bringer en historie uden at have fået den bekræftet fra nogen side. En forældet information fra CT er jo en ret dårlig kilde.

[nohope]

In this market with Trump fucking everything up nobody is looking for risc.

[nohope]

Even goog solid shares with low PE and high yield are beaten up.

[nohope]

Even good solid shares etc.

[Raffles]

Sloan Kettering Institute identifies new way to combat a serious CAR-T cell therapy side effect!! Det bliver spændende at følge! https://www.mskcc.org/blog/study-identifies-new-way-combat-serious-car-cell-therapy-side-effect?sf191604095=1#utm_source=Twitter&utm_medium=Organic&utm_campaign=062218Cart&utm_content=Research

[henrik48]

Det da godt nok lidt vanskeligt at blive klog på hvad der får Genmab til at stige eller falde ...

[peter12]

Denne presentation er vist ikke så gammel ? http://ir.genmab.com/static-files/883e0329-61cc-418c-8703-cf8cc8e010f1

[JKY_VH]

Vi er i + pt.

[Helge_LarsenPI-redaktør]

Det er algoritmehandel i A/B - gruppen som kører det løb. Nettosalget ændrer sig ikke meget.

[Helge_LarsenPI-redaktør]

Utroligt så nemt det er, at flytte kursen den ene eller anden vej.

[Bulder]

tak for den Raffles. det bliver ganske rigtigt spændende at følge om det har samme virkning i mennesker.

[Doc4]

@Bulder...hvis vi lever så længe;)...On average, preclinical research takes five to seven years and costs several million dollars to complete, according to FasterCures (a nonprofit organization dedicated to increasing the speed of drug discovery across all therapeutic areas). Once this work is done, the drug developer can apply to the FDA for approval to start clinical trials by submitting an investigational new drug application (IND).

[Doc4]

...These trials take another five to seven years to complete (and many more millions of dollars), before the developer can ask the FDA for approval to bring a drug to market.

[Doc4]

...On average, it takes a drug about 12 years to get from discovery to market, and it costs about $1.8 billion per drug that works. Only about one drug in 10,000 actually makes it. However, due to the rigorous processes of preclinical research, about one in five drugs that get an IND eventually make it through trials.http://quest.mda.org/article/why-does-it-take-so-long-go-mouse-man

[Bulder]

Mon ikke det kan gøres hurtigere her. Det er jo ikke ny medicin, men enten en afprøvning af om en i forvejen godkendt IL-1-blokker virker efter hensigten eller konstruktion af car-t-cellen så den selv hæmmer IL-1.